Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections



Rating:

Share or cite this content

Citations should be made in the following way:
N. Papadopoulos (Manchester, United Kingdom), S. Szefler (Aurora, CO, United States of America), L. Bacharier (Nashville, TN, United States of America), J. Maspero (Buenos Aires, Argentina), C. Domingo (Barcelona, Spain), N. Daizadeh (Cambridge, MA, United States of America), D. Lederer (Tarrytown, NY, United States of America), M. Hardin (Cambridge, MA, United States of America), J. Jacob-Nara (Cambridge, MA, United States of America), Y. Deniz (Tarrytown, NY, United States of America), R. Gall (Tarrytown, NY, United States of America), B. Ortiz (Tarrytown, NY, United States of America), M. Djandji (Cambridge, MA, United States of America), P. Rowe (Bridgewater, NJ, United States of America). Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype. 2568

Member's Comments

No comment yet.

Related content which might interest you: Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 IL-33 in patients with severe uncontrolled allergic asthma Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017 Omalizumab in children with severe persistent allergic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Efficacy of tezepelumab in adolescents with severe, uncontrolled asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Immunotherapy in severe asthma Source: ERS webinar 2021: Immunotherapy in severe asthma Year: 2021 A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021 Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005 Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019 Year: 2020 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008